Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 17/20 | 0.79 |
| ▸ | NEK6 | Q9HC98 | 2/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.61 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.61 |
| ▸ | MELK | Q14680 | 1/20 | 0.61 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | PLK1 | P53350 | 3/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.56 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527318 | 0.93 | TTK (0.68) | TTKNEK6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL525530 | 0.92 | TTK (0.92) | TTKAURKAPLK1PLK3PLK2 | |
| SCHEMBL526126 | 0.91 | TTK (0.79) | TTKNEK6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1559108 | 0.89 | TTK (0.85) | TTKNEK6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL12698424 | 0.88 | TTK (1.00) | TTKAURKAPLK1PLK3PLK2 | |
| SCHEMBL10092918 | 0.87 | PLK1 (0.67) | TTKNEK6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10092916 | 0.87 | PLK1 (0.68) | TTKNEK6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL526178 | 0.86 | PLK1 (0.59) | TTKNEK6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL526085 | 0.86 | TTK (0.82) | TTKAURKAPLK1PLK3PLK2 | |
| SCHEMBL14990270 | 0.85 | TTK (0.70) | TTKNEK6CSNK2A2MELKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | claimed |
| EP-2598508-B1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-22 | — | — | EP | claimed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | claimed |
| US-9333205-B2 | Isoxazolo-quinazolines as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| EP-2598508-B1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-22 | — | — | EP | disclosed |
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
| EP-2598508-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Nerviano Medical Sciences S.r.l. (IT) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013557-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | CSNK1A1, RPS6KA1, CSNK2A1 | TTK 341/4885NEK6 1150/4885CSNK2A2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.